HERS Protocol 2 — Hepatic Encephalopathy Recovery & Support
Managing HE with NASH / NAFLD CirrhosisNon-Alcoholic Fatty Liver Disease — Adapted Protocol
← Back to main protocol (alcohol-related HE)
This protocol is adapted for patients whose HE arises from NASH or NAFLD-related cirrhosis rather than alcohol use. The core interventions overlap significantly with the main protocol, but the metabolic context introduces specific differences — particularly around sugar, insulin resistance, Vitamin E, and thiamine considerations. Not a replacement for medical care.
⚡ What's Different for NASH/NAFLD
The core mechanisms of HE — elevated ammonia, gut dysbiosis, impaired urea cycle — are the same regardless of cause. What changes with NASH/NAFLD is the metabolic context:
- No alcohol history — thiamine deficiency is less likely, though not impossible
- Insulin resistance and metabolic syndrome are often present and directly worsen liver function and HE outcomes
- Sugar and fructose restriction is especially critical — these are primary drivers of NASH progression
- Vitamin E has RCT-level evidence specifically in NASH (not other liver disease subtypes) and belongs in this protocol
- Sarcopenia is often underrecognized in NASH patients who may not appear malnourished — protein adequacy matters just as much
- Thiamine supplementation is still reasonable but the urgency of the alcohol-related protocol is reduced unless alcohol use is also present
Understanding HE in NASH Cirrhosis
NASH (Non-Alcoholic Steatohepatitis) and NAFLD (Non-Alcoholic Fatty Liver Disease) have become the leading causes of cirrhosis in many countries, driven by the metabolic syndrome epidemic. When NAFLD progresses to cirrhosis, the liver loses its capacity to clear ammonia just as in alcohol-related cirrhosis — the pathway to HE is identical. What differs is the broader metabolic environment in which it occurs.
In NASH cirrhosis, the liver has been damaged by lipid accumulation, inflammation, and fibrosis over years — often silently. Patients frequently have comorbid Type 2 diabetes or insulin resistance, obesity, and dyslipidemia. These conditions are not merely background — they actively affect ammonia production, gut permeability, microbiome composition, and the liver's residual metabolic capacity.
The good news: the same affordable alternative stack that supports alcohol-related HE recovery applies here, with a few meaningful additions and adjustments.
The Core Stack — Same Foundation, Adapted
Replaces Lactulose
MiraLax (Polyethylene Glycol 3350)
1 capful daily — titrate to 2–3 soft, formed stools per day
Identical rationale to the main protocol. Bowel management is the first line of ammonia control. The electrolyte depletion concern is generally less acute in NASH patients not coming off alcohol, but controlled stool frequency remains critical.
Core Ammonia Reduction — Begin Day One
LOLA (L-Ornithine L-Aspartate)
Start 6g/day (3g morning, 3g evening). Titrate over week one to 18g/day (6g three times daily).
LOLA supports the urea cycle directly. The evidence base applies regardless of the cause of cirrhosis — the target mechanism (ammonia accumulation from impaired urea synthesis) is identical. (Goh et al., Cochrane, 2018.)
Sourcing: BulkSupplements.com — pharmaceutical-grade LOLA powder, COA available, 1kg quantity. Digital milligram scale essential.
NASH-Specific Addition
Vitamin E (alpha-tocopherol, non-esterified)
800 IU daily — with a fat-containing meal
This is the only supplement in this protocol with an RCT specifically in NASH (not liver disease generally). The PIVENS trial demonstrated that Vitamin E at 800 IU/day significantly improved liver histology — including inflammation and hepatocyte ballooning — in non-diabetic adults with NASH. AASLD guidelines recommend Vitamin E as a first-line pharmacotherapy option for non-diabetic NASH. It does not directly treat HE, but it addresses the underlying inflammatory hepatic injury driving disease progression.
Important limitation: The evidence applies to non-diabetic patients specifically. In diabetic patients, benefit is less established and some meta-analyses show neutral effects. The dose of 800 IU is the studied dose — do not exceed 1,000 IU without medical guidance. Long-term very high-dose Vitamin E (2,000+ IU) has been associated with increased all-cause mortality in some analyses; the 800 IU evidence is more favorable. Use natural alpha-tocopherol (d-alpha-tocopherol), not synthetic (dl-alpha-tocopherol).
Important limitation: The evidence applies to non-diabetic patients specifically. In diabetic patients, benefit is less established and some meta-analyses show neutral effects. The dose of 800 IU is the studied dose — do not exceed 1,000 IU without medical guidance. Long-term very high-dose Vitamin E (2,000+ IU) has been associated with increased all-cause mortality in some analyses; the 800 IU evidence is more favorable. Use natural alpha-tocopherol (d-alpha-tocopherol), not synthetic (dl-alpha-tocopherol).
Gut Microbiome — Prebiotic
Sunfiber (Partially Hydrolyzed Guar Gum)
Per label — mixes invisibly into any drink
Gut dysbiosis in NASH is well-characterized — Proteobacteria overgrowth and intestinal permeability are central features of NAFLD progression. Prebiotic fiber addresses both. The NASH-specific microbiome is often more disrupted by the metabolic syndrome environment than by alcohol per se, making this component especially relevant.
Gut Microbiome — Probiotic
Visbiome (or quality Lactobacillus-dominant probiotic)
10–50 billion CFU once daily
Probiotic use in NASH has independent evidence beyond HE management — multiple RCTs show improvements in liver enzymes, lipid profiles, and insulin sensitivity alongside ammonia-related benefits. Both the HE and the metabolic disease benefit from this intervention.
Insulin Sensitivity Support
Berberine
500mg twice daily with meals — if not on metformin or other glucose-lowering medication
Berberine is a botanical alkaloid with documented effects on insulin resistance, hepatic lipid accumulation, and gut microbiome composition. Multiple meta-analyses show it reduces fasting glucose, HbA1c, and liver enzymes (ALT/AST) in NAFLD patients comparably to metformin in some studies. In the NASH/HE context, improving insulin resistance reduces hepatic fat accumulation and inflammation, directly supporting liver recovery.
Important: Do not combine with metformin, sulfonylureas, or other glucose-lowering medications without medical guidance — additive hypoglycemia risk. Not appropriate if already on diabetes medications without provider awareness. Check for drug interactions — berberine is a CYP3A4 inhibitor.
Important: Do not combine with metformin, sulfonylureas, or other glucose-lowering medications without medical guidance — additive hypoglycemia risk. Not appropriate if already on diabetes medications without provider awareness. Check for drug interactions — berberine is a CYP3A4 inhibitor.
Urea Cycle Cofactor
Zinc (gluconate or bisglycinate)
25mg daily maintenance
Zinc deficiency is present in NASH cirrhosis as it is in alcohol-related cirrhosis, through different mechanisms — predominantly reduced dietary intake and impaired hepatic zinc metabolism. Cofactor support for the urea cycle is equally applicable.
Muscle & Liver Support
BCAAs (Branched-Chain Amino Acids)
12–20g/day, evening alongside casein
Sarcopenia is common in NASH cirrhosis and often underrecognized — patients may not look malnourished but may have significant functional muscle loss. BCAAs support muscle preservation without adding hepatic metabolic burden.
Neuroprotective Support
Acetyl-L-Carnitine (ALCAR)
2g twice daily (4g/day)
Carnitine deficiency occurs in NASH-related cirrhosis. ALCAR's neuroprotective and ammonia-lowering effects apply regardless of the underlying cause of cirrhosis. Evidence base as described in main protocol.
Protein Timing — Critical
Casein (evening) + Protein every 3–4 hours
Total target: 1.2–1.5g protein per kg body weight per day. Do not fast beyond 4 hours.
Identical reasoning to main protocol. In NASH patients with comorbid obesity, there is sometimes a clinical hesitancy to recommend protein intake due to weight concerns — this is inappropriate. Adequate protein prevents sarcopenia and reduces the muscle-derived ammonia load from catabolism.
Daily Timing
Morning — with breakfast
B-50 Complex (thiamine urgency is less acute than in alcohol-related HE, but B vitamins remain important for hepatic metabolism) · Vitamin D3 + K2 · Vitamin E 800 IU (with food containing fat) · MiraLax · LOLA 6g · Sunfiber · Zinc 25mg · Probiotic · Berberine 500mg (if not on glucose-lowering meds)
Midday — with lunch
LOLA 6g · Berberine 500mg (second dose) · Protein source — do not allow 4 hours without food
Evening — with dinner / before bed
LOLA 6g · BCAAs 12–20g · ALCAR 2g · Casein protein · Magnesium Glycinate 400mg
Throughout the Day
Water consistently · Electrolytes daily (Pedialyte or homemade) · Avoid sedatives, antihistamines, and sleep aids
Diet — Especially Critical in NASH
Diet is the primary driver of NASH and is more directly modifiable than in alcohol-related disease. Sugar, fructose, and refined carbohydrates are the primary hepatic aggressors. This is not a "general healthy eating" recommendation — it is a disease-specific intervention with direct evidence.
- No fructose, no added sugar — strictly. This is the most important dietary rule for NASH. Fructose drives de novo hepatic lipogenesis directly and is the dominant dietary driver of NAFLD progression. This means no fruit juices, no high-fructose corn syrup, no honey in quantity, no agave. Whole fruit in moderation is acceptable — the fiber slows absorption. Stevia acceptable.
- No refined carbohydrates — white bread, white rice, crackers, pastries spike insulin and feed hepatic fat accumulation. Substitute: oats, quinoa, legumes, sweet potato.
- Protein preference: vegetable/dairy → eggs/fish → poultry → red meat last. Total 1.2–1.5g/kg/day.
- Moderate healthy fats: olive oil, avocado, nuts. These do not worsen NASH and support the fat-soluble Vitamin E absorption.
- No alcohol — even small amounts worsen NASH progression measurably.
- Plain unsweetened yogurt: excellent for potassium, magnesium, protein, and probiotics.
- Mediterranean dietary pattern is the most evidence-supported dietary framework for NASH specifically.
- Small, frequent meals — 4–6 per day. Large meals worsen postprandial insulin spikes.
📋 Labwork Priorities for NASH/NAFLD
In addition to the basic metabolic panel (potassium, magnesium, creatinine), the following labs are especially relevant in NASH patients:
- HbA1c and fasting insulin — assess degree of insulin resistance; guides berberine decision and dietary targets
- Lipid panel — dyslipidemia is common and affects cardiovascular risk in this population
- Vitamin D level — deficiency is highly prevalent in NASH and independently associated with worse liver histology
- Liver enzymes (ALT, AST, GGT) — baseline and trend; improvement indicates treatment response
- Potassium and magnesium — same importance as in all HE presentations
Know the Triggers
Infection — any fever warrants prompt attention; SBP can occur in NASH cirrhosis
Constipation — fewer than 2 BMs/day: add MiraLax dose
GI bleeding — dark/tarry stools or vomiting blood: emergency
Dehydration — from heat, illness, or over-diuresis
Fasting >4 hours — triggers muscle catabolism and ammonia production
Sugar binge or dietary lapse — can acutely worsen hepatic inflammation and precipitate decompensation in NASH
New medications — NSAIDs, acetaminophen at high doses, and many herbal supplements are hepatotoxic; check before taking
Constipation — fewer than 2 BMs/day: add MiraLax dose
GI bleeding — dark/tarry stools or vomiting blood: emergency
Dehydration — from heat, illness, or over-diuresis
Fasting >4 hours — triggers muscle catabolism and ammonia production
Sugar binge or dietary lapse — can acutely worsen hepatic inflammation and precipitate decompensation in NASH
New medications — NSAIDs, acetaminophen at high doses, and many herbal supplements are hepatotoxic; check before taking
Monitoring
Asterixis Check (Hand Flap Test)
Arms extended, palms up, eyes closed, hold still 15–20 seconds.
Watch for rhythmic, involuntary flapping. Note that in NASH patients without alcohol history, there is less medication-induced tremor to confuse the picture — new asterixis in this population is a clearer signal.
Daily Orientation Check
— What day is it? · Where are we? · What did you eat this morning? · Name of [family member]? Compare to yesterday. Any step backward over 24–48 hours warrants a call.
Bowel Movement Log
Target
2–3x/day, soft, formed
Too Little
0–1x or hard — increase MiraLax
Too Much
4+ or watery — reduce MiraLax, add electrolytes
Signs to Seek Care
- Asterixis new, returning, or worsening over consecutive days
- Clear step-backward in orientation or conversation over 24–48 hours
- Fever — primary HE trigger, warrants prompt attention
- Dark/tarry stools or vomiting blood — emergency
- Jaundice visibly deepening · Inability to keep fluids down 12+ hours
- Significant new abdominal swelling · Severe muscle cramping
- Any loss of consciousness · Diarrhea >24h despite reducing MiraLax
- Blood sugar going very high or very low if diabetic — both can precipitate confusion that mimics or compounds HE
NASH-related HE is an increasingly common presentation that gets less attention than alcohol-related disease — partly because it develops more quietly and partly because its metabolic roots make it feel less dramatic. It is not less serious. With consistent management of both the liver and the metabolic environment, meaningful recovery is achievable.
Key References
Sanyal AJ et al. Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis (PIVENS). NEJM, 2010.
Chalasani N et al. AASLD Practice Guidance for NAFLD. Hepatology, 2018.
Goh ET et al. LOLA for HE in cirrhosis. Cochrane Database, 2018.
Amodio P et al. Nutritional management of HE: ISHEN guidelines. Hepatology, 2013.
Rahimi RS et al. Lactulose vs PEG 3350 for Overt HE. JAMA Internal Medicine, 2014.
Yin J et al. Efficacy of Berberine in patients with type 2 diabetes. Metabolism, 2008.
EASL Guidelines on nutrition in chronic liver disease. Journal of Hepatology, 2019.